These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 30280368

  • 1. The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.
    Liu X, Li X, Li X, Li Z, Zhao D, Liu S, Zhang M, Zhang F, Zhu P, Chen J, Wei W, Lin B, Zhou Y, Chen J, Pang Y, Zhang L, Sun X, Yu Z, Jia Y, Wang J, Sun W, Chiu F, Pang L, Wang G.
    Clin Rheumatol; 2019 Mar; 38(3):657-664. PubMed ID: 30280368
    [Abstract] [Full Text] [Related]

  • 2. Clinical and immunological consequences of total glucosides of paeony treatment in Sjögren's syndrome: A randomized controlled pilot trial.
    Zhou Y, Jin L, Kong F, Zhang H, Fang X, Chen Z, Wang G, Li X, Li X.
    Int Immunopharmacol; 2016 Oct; 39():314-319. PubMed ID: 27517517
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial.
    Shao Q, Wang S, Jiang H, Liu L.
    Scand J Rheumatol; 2021 Mar; 50(2):143-152. PubMed ID: 33118847
    [Abstract] [Full Text] [Related]

  • 4. Traditional Chinese medicine compound ShengJinRunZaoYangXue granules for treatment of primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled clinical trial.
    Hu W, Qian X, Guo F, Zhang M, Lyu C, Tao J, Gao Z, Zhou Z.
    Chin Med J (Engl); 2014 Mar; 127(15):2721-6. PubMed ID: 25146603
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of belimumab in primary Sjögren's syndrome: results of the BELISS open-label phase II study.
    Mariette X, Seror R, Quartuccio L, Baron G, Salvin S, Fabris M, Desmoulins F, Nocturne G, Ravaud P, De Vita S.
    Ann Rheum Dis; 2015 Mar; 74(3):526-31. PubMed ID: 24347569
    [Abstract] [Full Text] [Related]

  • 6. The Effectiveness and Safety of Total Glucosides of Paeony in Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis.
    Feng Z, Zhang BQ, Zhu YM, Yu BB, Fu L, Zhou LL, Zhou XP, Lu Y.
    Front Pharmacol; 2019 Mar; 10():550. PubMed ID: 31178729
    [Abstract] [Full Text] [Related]

  • 7. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
    Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, Combe B, Puéchal X, Pennec Y, Sauvezie B, Perdriger A, Hayem G, Janin A, Sibilia J.
    Arthritis Rheum; 2004 Apr; 50(4):1270-6. PubMed ID: 15077311
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
    Bowman SJ, Fox R, Dörner T, Mariette X, Papas A, Grader-Beck T, Fisher BA, Barcelos F, De Vita S, Schulze-Koops H, Moots RJ, Junge G, Woznicki JN, Sopala MA, Luo WL, Hueber W.
    Lancet; 2022 Jan 08; 399(10320):161-171. PubMed ID: 34861168
    [Abstract] [Full Text] [Related]

  • 9. Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome.
    Bowman SJ, Everett CC, O'Dwyer JL, Emery P, Pitzalis C, Ng WF, Pease CT, Price EJ, Sutcliffe N, Gendi NST, Hall FC, Ruddock SP, Fernandez C, Reynolds C, Hulme CT, Davies KA, Edwards CJ, Lanyon PC, Moots RJ, Roussou E, Giles IP, Sharples LD, Bombardieri M.
    Arthritis Rheumatol; 2017 Jul 08; 69(7):1440-1450. PubMed ID: 28296257
    [Abstract] [Full Text] [Related]

  • 10. Comparative analysis of the efficacy and safety of herbal decoction CheReCunJin alone and combined with hydroxychloroquine for treating primary Sjögren's syndrome: A randomized controlled trial.
    Shao Q, Jin L, Li C, Wang J, Wang M, Wang Q, Wu B.
    Explore (NY); 2022 Jul 08; 18(4):416-422. PubMed ID: 34417112
    [Abstract] [Full Text] [Related]

  • 11. Effects of total glucosides of peony on AQP-5 and its mRNA expression in submandibular glands of NOD mice with Sjogren's syndrome.
    Wu GL, Pu XH, Yu GY, Li TY.
    Eur Rev Med Pharmacol Sci; 2015 Jan 08; 19(1):173-8. PubMed ID: 25635992
    [Abstract] [Full Text] [Related]

  • 12. [Clinical observation on effect of total glucosides of paeony in treating patients with non-systemic involved Sjögren syndrome].
    Zhang HF, Hou P, Xiao WG.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Jul 08; 27(7):596-8. PubMed ID: 17717915
    [Abstract] [Full Text] [Related]

  • 13. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjögren's syndrome.
    Khurshudian AV.
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2003 Jan 08; 95(1):38-44. PubMed ID: 12539025
    [Abstract] [Full Text] [Related]

  • 14. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
    Dörner T, Posch MG, Li Y, Petricoul O, Cabanski M, Milojevic JM, Kamphausen E, Valentin MA, Simonett C, Mooney L, Hüser A, Gram H, Wagner FD, Oliver SJ.
    Ann Rheum Dis; 2019 May 08; 78(5):641-647. PubMed ID: 30826774
    [Abstract] [Full Text] [Related]

  • 15. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM, Arends S, Brouwer E, Spijkervet FK, Vissink A, Bootsma H.
    Ann Rheum Dis; 2012 Aug 08; 71(8):1297-302. PubMed ID: 22258489
    [Abstract] [Full Text] [Related]

  • 16. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
    Cornec D, Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, Le Guern V, Sibilia J, Gottenberg JE, Chiche L, Hachulla E, Yves Hatron P, Goeb V, Hayem G, Morel J, Zarnitsky C, Dubost JJ, Saliou P, Pers JO, Seror R, Saraux A.
    Arthritis Care Res (Hoboken); 2017 Apr 08; 69(4):528-535. PubMed ID: 27390310
    [Abstract] [Full Text] [Related]

  • 17. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome.
    Juarez M, Diaz N, Johnston GI, Nayar S, Payne A, Helmer E, Cain D, Williams P, Devauchelle-Pensec V, Fisher BA, Giacomelli R, Gottenberg JE, Guggino G, Kvarnström M, Mariette X, Ng WF, Rosas J, Sánchez Bursón J, Triolo G, Barone F, Bowman SJ.
    Rheumatology (Oxford); 2021 Mar 02; 60(3):1364-1375. PubMed ID: 32949140
    [Abstract] [Full Text] [Related]

  • 18. ESSPRI and other patient-reported indices in patients with primary Sjogren's syndrome during 100 consecutive outpatient visits at one rheumatological clinic.
    Pertovaara M, Korpela M.
    Rheumatology (Oxford); 2014 May 02; 53(5):927-31. PubMed ID: 24464708
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
    Baer AN, Gottenberg JE, St Clair EW, Sumida T, Takeuchi T, Seror R, Foulks G, Nys M, Mukherjee S, Wong R, Ray N, Bootsma H.
    Ann Rheum Dis; 2021 Mar 02; 80(3):339-348. PubMed ID: 33168545
    [Abstract] [Full Text] [Related]

  • 20. Baseline disease activity influences subsequent achievement of patient acceptable symptom state in Sjögren's syndrome.
    Park EH, Ha YJ, Kang EH, Song YW, Scofield RH, Lee YJ.
    Rheumatology (Oxford); 2021 Jun 18; 60(6):2714-2724. PubMed ID: 33188390
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.